|
Volumn 3, Issue 2, 2008, Pages 132-142
|
Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ADRENERGIC RECEPTOR AFFECTING AGENT;
ALANINE AMINOTRANSFERASE;
ALKALINE PHOSPHATASE;
ASPARTATE AMINOTRANSFERASE;
BILIRUBIN;
BIOLOGICAL MARKER;
DULOXETINE;
SEROTONIN UPTAKE INHIBITOR;
THIOPHENE DERIVATIVE;
ANIMAL;
BLOOD;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DRUG EFFECT;
DRUG SCREENING;
ENZYMOLOGY;
HUMAN;
LIVER;
LIVER DISEASE;
REVIEW;
RISK ASSESSMENT;
RISK FACTOR;
SAFETY;
SPECIES DIFFERENCE;
ADRENERGIC UPTAKE INHIBITORS;
ALANINE TRANSAMINASE;
ALKALINE PHOSPHATASE;
ANIMALS;
ASPARTATE AMINOTRANSFERASES;
BILIRUBIN;
BIOLOGICAL MARKERS;
CLINICAL TRIALS AS TOPIC;
CONSUMER PRODUCT SAFETY;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
LIVER;
LIVER DISEASES;
RISK ASSESSMENT;
RISK FACTORS;
SEROTONIN UPTAKE INHIBITORS;
SPECIES SPECIFICITY;
THIOPHENES;
|
EID: 66749155881
PISSN: 15748863
EISSN: None
Source Type: Journal
DOI: 10.2174/157488608784529189 Document Type: Review |
Times cited : (37)
|
References (30)
|